| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8442087 | European Journal of Cancer | 2015 | 9 Pages |
Abstract
The addition of selumetinib to fulvestrant did not show improving patients' outcome and was poorly tolerated at the recommended monotherapy dose. Selumetinib may have deteriorated the efficacy of the endocrine therapy in some patients.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Khalil Zaman, Ralph Winterhalder, Christoph Mamot, Ursula Hasler-Strub, Christoph Rochlitz, Andreas Mueller, Catherine Berset, Hans Wiliders, Lucien Perey, Christine Biaggi Rudolf, Hanne Hawle, Stephanie Rondeau, Patrick Neven,